Cellectis P/E Ratio

Cellectis (CLLS) currently reports a P/E ratio of -5.39. That is below the Healthcare sector average of 25.9. Use the charts on this page to explore Cellectis's P/E ratio history and peer comparisons.

Cellectis's P/E ratio of -5.39 is lower than the Healthcare sector average of 25.9. That is roughly 120.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The P/E ratio is a valuation multiple that relates Cellectis's market price to a fundamental measure such as earnings, sales, or book value. At -5.39, CLLS can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current P/E ratio of -5.39, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 25.9. From there, open related valuation or income-statement pages for Cellectis, and consider following CLLS for alerts when major investors trade the stock.

Cellectis is classified in the Healthcare sector. On P/E ratio, it currently shows -5.39 versus a sector average near 25.9. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CLLS with unrelated industries.